Julian Baker Baker Bros. Advisors
Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Immunovant
IMVT
|
+$78.4M |
| 2 |
Vaxcyte
PCVX
|
+$47.3M |
| 3 |
Insmed
INSM
|
+$28.6M |
| 4 |
Immunocore
IMCR
|
+$24.2M |
| 5 |
Celcuity
CELC
|
+$17.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONC
BeOne Medicines Ltd
ONC
|
+$171M |
| 2 |
CRISPR Therapeutics
CRSP
|
+$27.7M |
| 3 |
Krystal Biotech
KRYS
|
+$26.6M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
+$26.6M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$24.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.87% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Xencor
XNCR
$2.07B
| $7.13M | 0.08% |
670,431
| – | – |
|
52
Dyne Therapeutics
DYN
$4.87B
| $7.03M | 0.08% |
672,096
| – | – |
|
53
KALA BIO
KALA
$15.9M
| $6.89M | 0.08% |
24,038
| – | – |
|
54
Design Therapeutics
DSGN
$938M
| $6.73M | 0.07% |
1,743,725
| – | – |
|
55
Structure Therapeutics
GPCR
$3.5B
| $6.26M | 0.07% |
361,565
| – | – |
|
56
Taysha Gene Therapies
TSHA
$1.98B
| $5.57M | 0.06% |
4,004,756
| – | – |
|
|
RGLS
57
DELISTED
Regulus Therapeutics
RGLS
| $4.71M | 0.05% |
+2,694,044
| New | +$3.55M |
|
|
IGMS
58
DELISTED
IGM Biosciences
IGMS
| $4.71M | 0.05% |
4,095,257
+953
| +0% | +$1.77K |
|
59
Intellia Therapeutics
NTLA
$1.8B
| $4.58M | 0.05% |
644,116
| – | – |
|
60
Celldex Therapeutics
CLDX
$3.17B
| $4.49M | 0.05% |
247,644
| – | – |
|
|
SION
61
Sionna Therapeutics
SION
$239M
| $4.18M | 0.05% |
+400,000
| New | +$6.54M |
|
62
BioNTech
BNTX
$29.3B
| $4.1M | 0.05% |
45,031
| – | – |
|
63
TScan Therapeutics
TCRX
$52.8M
| $3.84M | 0.04% |
2,784,792
| – | – |
|
64
Disc Medicine
IRON
$3.06B
| $3.82M | 0.04% |
77,050
| – | – |
|
65
Vir Biotechnology
VIR
$1.65B
| $3.52M | 0.04% |
542,539
-542,000
| -50% | -$4.82M |
|
66
Sana Biotechnology
SANA
$1.17B
| $3.41M | 0.04% |
2,030,949
-350,000
| -15% | -$978K |
|
67
Sagimet Biosciences
SGMT
$637M
| $3.11M | 0.03% |
952,996
| – | – |
|
68
Relay Therapeutics
RLAY
$4.26B
| $3.04M | 0.03% |
1,160,117
| – | – |
|
69
Wave Life Sciences
WVE
$1.04B
| $2.78M | 0.03% |
344,063
| – | – |
|
70
Fate Therapeutics
FATE
$279M
| $2.57M | 0.03% |
3,258,402
| – | – |
|
71
Skye Bioscience
SKYE
$1.24M
| $2.31M | 0.03% |
1,450,638
| – | – |
|
72
Protara Therapeutics
TARA
$228M
| $2.29M | 0.03% |
536,832
| – | – |
|
73
Enliven Therapeutics
ELVN
$4.38B
| $2.26M | 0.03% |
114,833
| – | – |
|
|
CTNM
74
Contineum Therapeutics
CTNM
$647M
| $2.18M | 0.02% |
312,500
| – | – |
|
75
Prime Medicine
PRME
$615M
| $2.05M | 0.02% |
1,028,466
| – | – |
|
Similar funds
Julian Baker's Q1 2025 Portfolio in Review
As of Q1 2025, Julian Baker held 98 positions worth $9.04B, down 3.5% from $9.36B the previous quarter. Its ten largest holdings account for 82% of the portfolio.
Julian Baker's Q1 2025 filing shows 4 new, 11 increased, 16 reduced and 9 closed positions. Its largest new stake was Verona Pharma: 223,843 shares worth $14.2M. The largest sale was BeOne Medicines Ltd, an estimated $171M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.
- Julian Baker's largest Q1 2025 buy was Verona Pharma: 223,843 shares worth $14.2M.
- Julian Baker added most to Immunovant in Q1 2025, an estimated $78.4M increase.
- Julian Baker's biggest Q1 2025 reduction was BeOne Medicines Ltd, cutting an estimated $171M.
- Julian Baker fully exited Krystal Biotech in Q1 2025, selling an estimated $26.6M.
- Julian Baker's ten largest holdings make up 82% of its $9.04B portfolio in Q1 2025.
- Julian Baker opened 4 new positions and closed 9 in Q1 2025.
- Julian Baker's portfolio value fell 3.5% quarter-over-quarter to $9.04B.
Based on Baker Bros. Advisors's 13F filing for Q1 2025, filed 15 May 2025.